|3Feb 4, 9:52 PM ET

PureTech Health LLC 3

3 · Vor Biopharma Inc. · Filed Feb 4, 2021

Insider Transaction Report

Form 3
Period: 2021-02-04
Holdings
  • Series A-1 Preferred Stock

    Common Stock (1,470,588 underlying)
  • Series A-2 Preferred Stock

    Common Stock (1,595,210 underlying)
  • Series B Preferred Stock

    Common Stock (141,402 underlying)
Footnotes (1)
  • [F1]Each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 13.6-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

Documents

1 file
  • 3
    doc3.xmlPrimary

    FORM 3 SUBMISSION